The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Assessment of Plasma Proteomics Biomarker’s Ability to Distinguish Benign From Malignant Lung Nodules
Open accessAbstract
BACKGROUND: Lung nodules are a diagnostic challenge, with an estimated yearly incidence of 1.6 million in the United States. This study evaluated the accuracy of an integrated proteomic classifier in identifying benign nodules in patients with a pretest probability of cancer (pCA) ≤ 50%. METHODS: A prospective, multicenter observational trial of 685 patients with 8- to 30-mm lung nodules was conducted. Multiple reaction monitoring mass spectrometry was used to measure the relative abundance of two plasma proteins, LG3BP and C163A. Results were integrated with a clinical risk prediction model to identify likely benign nodules. Sensitivity, specificity, and negative predictive value were calculated. Estimates of potential changes in invasive testing had the integrated classifier results been available and acted on were made. RESULTS: A subgroup of 178 patients with a clinician-assessed pCA ≤ 50% had a 16% prevalence of lung cancer. The integrated classifier demonstrated a sensitivity of 97% (CI, 82-100), a specificity of 44% (CI, 36-52), and a negative predictive value of 98% (CI, 92-100) in distinguishing benign from malignant nodules. The classifier performed better than PET, validated lung nodule risk models, and physician cancer probability estimates (P < .001). If the integrated classifier results were used to direct care, 40% fewer procedures would be performed on benign nodules, and 3% of malignant nodules would be misclassified. CONCLUSIONS: When used in patients with lung nodules with a pCA ≤ 50%, the integrated classifier accurately identifies benign lung nodules with good performance characteristics. If used in clinical practice, invasive procedures could be reduced by diverting benign nodules to surveillance. TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT01752114; URL: www.clinicaltrials.gov).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening
The National Lung Screening Trial Research Team (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1102873 · Cited by 11,064
Cited by
Biomarkers in Lung Cancer Screening: Achievements, Promises, and Challenges
Seijo, L. M., Peled, N., Ajona, D., Boeri, M., Field, J. K., Sozzi, G., Pio, R., Zulueta, J. J., Spira, A., Massion, P. P., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.11.023 · Cited by 539
Self-citationEvaluating the Patient With a Pulmonary Nodule: A Review
Mazzone, P. J., & Lam, L. (2022) · JAMA · doi:10.1001/jama.2021.24287 · Cited by 487
Self-citationNasrullah, N., Sang, J., Alam, M. S., Mateen, M., Cai, B., & Hu, H. (2019) · Sensors · doi:10.3390/s19173722 · Cited by 359
Risk-Based lung cancer screening: A systematic review
Toumazis, I., Bastani, M., Han, S. S., & Plevritis, S. K. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.07.007 · Cited by 270
Clinical potential of mass spectrometry-based proteogenomics
Zhang, B., Whiteaker, J. R., Hoofnagle, A. N., Baird, G. S., Rodland, K. D., & Paulovich, A. G. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0135-7 · Cited by 210
Metadata
- Authors
- Silvestri, G. A., Tanner, N. T., Kearney, P., Vachani, A., Massion, P. P., Porter, A., Springmeyer, S. C., Fang, K. C., Midthun, D., Mazzone, P. J., Silvestri, G. A., Leake, L., Mazzone, P., Beukemann, M., Midthun, D., McCarthy, P., Sigal, B., Deluca, T., Laberge, F., Fortin, B., Balaan, M., Dimitt, B., Pierre, A., Allison, F., Yarmus, L., Oakjones-Burgess, K., Tanner, N., Leake, L., Ettinger, N., Setchfield, T., Madtes, D., Hubbard, J., McConnell, W., Robinson, K., Lackey, A., Jacques, L., Kuo, E., Markland-Gentles, V., Massion, P., Muterspaug, A., Leach, J., Rothe, K., Rom, W., Pass, H., Sorenson, A., Chesnutt, A., Georgeson, A., Balekian, A., Fisher, J., Murali, R., Overton, A., Desai, N., Levesque, A., Krimsky, W., King, S., Vachani, A., Maletteri, K., Mileham, K., Carter, L., Hong, G., Ma, J., Voelker, K., Barrentine, H., Aronson, R., Henderson, M., Lamberti, J., Krawiecki, C., Case, A., Wilkins, L., Ayers, J. M., Fangmann, K., Landis, J., DeSouza, L., Hammoud, Z., Kah, D., Sanchez, J., & Murdoch, L.
- Venue
- Chest
- Publisher
- Elsevier BV
- Published
- 2018-09
- Volume
- 154
- Issue
- 3
- Pages
- 491-500
- ISSN
- 0012-3692 (ISSN-L)
- OpenAlex
- W2788104423
- Cited by
- 165
- References
- 1
- FWCI
- 10.31
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Assessment of Plasma Proteomics Biomarker’s Ability to Distinguish Benign From Malignant Lung Nodules. https://app.cochat.ai/papers/10.1016/j.chest.2018.02.012
- The paper
- Silvestri, G. A., Tanner, N. T., Kearney, P., Vachani, A., Massion, P. P., Porter, A., Springmeyer, S. C., Fang, K. C., Midthun, D., Mazzone, P. J., Silvestri, G. A., Leake, L., Mazzone, P., Beukemann, M., Midthun, D., McCarthy, P., Sigal, B., Deluca, T., Laberge, F., . . . Murdoch, L. (2018). Assessment of Plasma Proteomics Biomarker’s Ability to Distinguish Benign From Malignant Lung Nodules. Chest. https://doi.org/10.1016/j.chest.2018.02.012
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.